



Dynamics of STIs during and after the COVID-19 pandemic in PrEP-cohort at the University Medical Center Hamburg-Eppendorf (UKE)


Steinhaus N. J. ¹, Almahfoud M. ¹, Weimann L. ¹, Matthews H. ¹, Diekhoff P. ¹, Pollich S. ¹, Jordan S. ^{1,2}, Koch T. ², Schäfer G. ³, Hüfner A. ¹, Schmiedel S. ^{1,2} Schulze zur Wiesch J. ^{1,2}, Degen O. ¹

- ¹ Outpatient center Department for infectious diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- ² I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- ³ Infektionsmedizinisches Centrum Hamburg (ICH) Study Center, Hamburg, Germany.


Background:

Pre-exposure prophylaxis (PrEP) for HIV prevention is highly effective in reducing the risk of HIV infection in high-risk populations. Besides HIV prevention, regular screening for other sexually transmitted infections (STIs) remains critical due to potential shifts in sexual behavior and STI epidemiology. The COVID-19 pandemic has significantly impacted social interactions and may have altered sexual behavior, potentially influencing the transmission patterns of non-HIV STIs. This study aims to assess the changes in diagnoses and positivity rates for gonorrhea, syphilis, and chlamydia among PrEP users at the University Medical Center Hamburg-Eppendorf (UKE) during and after the pandemic.

Total number of STI diagnoses



Total Number of Tests Over Time (n=3778)




Results:

- Analysis of 3778 tests from 701 individuals revealed 522 positive diagnoses overall
- Diagnoses included **215 gonococcal**, **61 syphilis** and **246 chlamydia infections**
- **Stable positivity rates** for chlamydia and syphilis, and **low gonococci rates** during lockdowns (Q2 '20 Q1 '21), followed by an **increase in gonococci** starting in Q4 '21 and remaining elevated in 2022 (p=0.08)
- Comparing Covid- and Non-Covid periods showed **higher chlamydia positivity rates during 2022** (vs. 2021; p=0,172), while **gonococci rates were elevated 2022** (vs. 2021; p=0,174); **syphilis** positivity stayed consistently low with a **slight decline** after Q2 '22 (p=0.16)
- Stabilization from Q3 '22 through Q4 '23, with chlamydia and gonococci at a higher baseline positivity rate (Gonococci: 95%-CI=4.71–7.69; Chlamydia: 95%-CI=5.84–8.14); syphilis remained unchanged

Methods:

At the Outpatient center for Infectious Diseases at the University Medical Center Hamburg-Eppendorf (UKE), we have been following a **PrEP cohort** since **October 2020** as part of an ongoing prospective observational study. We use recurring **online questionnaires** (RedCap®), **standard blood tests and STI tests**. We analyzed the data collected in the period from Q1 2020 to Q4 2023. **Positivity rates** were calculated for each quarter **during and after the pandemic** using RedCap® and Excel®. We used AI tools (DeepL®, ChatGPT®) for translation and text editing. Standard descriptive statistic methods were employed.

STI Positivity Rate (%) Relative to Testing Volume



Conclusions:

- The increase in gonococcal positivity rates in Q4 2021 likely reflects catch-up effects following eased restrictions, while chlamydia rates remained stable during lockdowns
- > Syphilis's consistently low rates indicate distinct transmission dynamics with no significant rebound observed within the cohort
- The divergent trends in gonococcal, chlamydial, and syphilis positivity rates underscore the need for dynamic prevention strategies tailored to each STI's unique transmission pattern